|
Non-executive Chairman. Former head of Shield Diagnostics (now Axis-Shield plc), where he spearheaded the initial stages of development of a new diagnostic for heart problems. Mr. Hall has also held senior positions at US healthcare giant Abbott. He was appointed to the Board as executive Chairman in September 1998, becoming non-executive Chairman in February 2001. (Date of Birth – 18 August 1942)
Chief Executive Officer. Formerly COO at Osmetech for more than 2 years and was instrumental in the restructuring of the organisation as a medical devices company. He was appointed Chief Executive Officer in December 2000. Prior to joining Osmetech, Mr. White was a senior consultant in Arthur D. Little Ltd's corporate finance practice. As Chief Executive Officer and an Executive Director, Mr White has overall responsibility for the strategic development of the Group.(Date of Birth – 30 November 1970)
Non-executive Director from September 2002. Appointed to the Board in February 1998 as Director of Development and was appointed Chief Technology Officer in October 1999. Founder and former Chief Executive of Neopath, a diagnostic imaging company, and Advanced Technology Labs, a medical diagnostic ultrasound company later acquired by Squibb Corporation. Mr Kuenster is also Chairman of UMD Technology Inc. (Date of Birth – 9 November 1933)
Chief Financial Officer. Previously Group Finance Director of London-listed Bluebird Toys, until its take-over by Mattel Inc. Mr. Sandilands qualified as a Chartered Accountant with Price Waterhouse. He was appointed to the Board in July 1999. As Chief Financial Officer and an Executive Director, Mr Sandilands is responsible for the Group's financial reporting, treasury and financial management functions. (Date of Birth – 11 April 1961)
President of OMD. Previously Executive Vice President and Chief Operating Officer of Gen-Probe and President and Chief Operating Officer of Nanogen, two major international companies in the genetics and infectious diseases markets. He joined Osmetech in April 2005 as President of Clinical Micro Sensors and was appointed to the Board in February 2007. As President of OMD and an Executive Director, Mr Huebner is responsible for the management and development and of the Molecular Diagnostics division. (Date of Birth: 4 September 1950)
VP Molecular Diagnostics R&D and Business Development. Formerly Sr. Director Business Development bioMérieux North America with responsibility for new technologies for its molecular biology business. Dr. McKinley also successfully in-licensed technology from Gen-Probe (TMA) and Affymetrix (DNA-chip).
|
